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Abstract
A missense mutation of the guanine nucleotide binding protein alpha stimulating activity polypeptide 1 (GNAS) gene, typi-
cally Arg201Cys or Arg201His (R201H/R201C), leads to constitutive activation of the Gsa-cyclic AMP (cAMP) signaling
pathway that causes several diseases. However, no germline mutations of GNAS have been identified to date, likely due
to their lethality, and no robust human cell models have been generated. Therefore, the aim of this study was to gener-
ate GNAS-mutated disease-specific induced pluripotent stem cells as a model for these diseases. We then analyzed the
functionality of this induced pluripotent stem cell model and differentiated epithelial cells. We generated disease-specific
induced pluripotent stem cells by introducing a mutation in GNAS with the clustered regularly interspaced short palin-
dromic repeats (CRISPR) nickase method, which has lower off-target effects than the conventional CRISPR/Cas9
method. We designed the target vector to contain the R201H mutation in GNAS, which was transfected into human con-
trol induced pluripotent stem cells (Nips-B2) by electroporation. We confirmed the establishment of GNASR201H -
mutated (GNASR201H/+) induced pluripotent stem cells that exhibited a pluripotent stem cell phenotype. We analyzed
the effect of the mutation on cAMP production, and further generated teratomas for immunohistochemical analysis of
the luminal epithelial structure. GNAS-mutated induced pluripotent stem cells showed significantly higher levels of intra-
cellular cAMP, which remained elevated state for a long time upon hormonal stimulation with parathyroid hormone or
adrenocorticotropic hormone. Immunohistochemical analysis revealed that several mucins, including MUC1, 2, and
MUC5AC, are expressed in cytokeratin 18 (CK18)-positive epithelial cells. However, we found few CK18-positive cells
in mutated induced pluripotent stem cell–derived teratoma tissues, and reduced MUCINs expression in mutated epithe-
lial cells. There was no difference in CDX2 expression; however, mutated epithelial cells were positive for CEA and
CA19-9 expression. GNASR201H-mutated induced pluripotent stem cells and GNASR201H-mutated epithelial cells have dis-
tinct phenotypic and differentiation characteristics. We successfully established GNASR201H-mutated human induced plur-
ipotent stem cells with increased cAMP production. Considering the differentiation potential of induced pluripotent
stem cells, these cells will be useful as a model for elucidating the pathological mechanisms of GNAS-mutated diseases.
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Introduction
Guanine nucleotide binding protein alpha stimulating
activity polypeptide 1 (GNAS) stimulates the activity
the adenylate cyclase enzyme, which controls the activ-
ity of many hormones and cytokines.1,2 The GNAS
gene on the long arm of human chromosome 20 pro-
duces multiple gene products, including the alpha subu-
nit of the stimulating guanine nucleotide binding
protein (Gsa), a signaling protein that mediates effects
through the generation of the secondary messenger
cAMP, extra-large Gsa (XLas), A/B (also referred to as
1A), and neuroendocrine secretory protein (NESP55).3–7
GNAS also results in transcripts for coding and non-
coding regions that are derived from particular alleles of
a parent. The transcriptional and splicing profiles of
GNAS are very complex. In the process of transcription
initiation and RNA processing, NESP55, XLas, and A/
B individually initiate transcription from their own exon
1 using unique promoters, and the transcript is further
spliced onto exons 2–13. Gsa is biallelically expressed in
most tissues. However, GNAS gives rise to other gene
products, most of which exhibit exclusively monoallelic
expression.
Multiple differentially methylated regions (DMRs)
are located within the GNAS locus, which contains dif-
ferent promoters. Due to silencing of the GNAS pro-
moter at the methylated allele, XLa, A/B, and GNAS-
AS1 transcripts are expressed only in the paternal line,
whereas NESP55 transcripts are expressed only in the
maternal line.8 The underlying mechanism of the tissue-
specific maternal expression of Gsa is not well under-
stood. However, it is clear that this epigenetic event sig-
nificantly contributes to the parent-of-origin–specific
phenotypic changes of GNAS mutation.
The GNASR201H and GNASR201C mutations are as-
sociated with several highly specific pathological mole-
cular phenotypes. However, both mutations activate
the GNAS-cAMP pathway, and no major differences
in disease development have been reported. McCune–
Albright syndrome (MAS) is one of the most well-
characterized GNAS mutation-related rare genetic dis-
order that was originally characterized as a disease with
a triad of polyostotic fibrous dysplasia (FD) of the
bone, gonadotropin-independent precocious puberty,
and café-au-lait skin pigmentation.9 However, there
does not appear to be a parental allele bias in patients
with MAS.10
GNASR201H/C mutations have been linked to low-
grade and benign tumors, especially gastrointestinal or
pancreatic lesions.11,12 Intraductal papillary mucinous
neoplasms (IPMNs) often have a somatic GNASR201H/C
mutation. Gastric lesions that harbor GNAS mutations
have also been observed in pyloric gland adenomas,
oxyntic gland adenomas, gastric heterotopia, and gas-
tric mucin cell metaplasia of the stomach.13,14 Since a
GNAS point mutation can cause different diseases, gen-
eration of induced pluripotent stem cells (iPSCs) with
this mutation would be useful for studying these dis-
eases in more detail.15
Emerging gene editing technology using the clus-
tered regularly interspaced short palindromic repeats
(CRISPR) system has provided new investigative
opportunities.16–20 CRISPR-associated protein 9
(Cas9) nuclease guided by short single guide RNAs
(sgRNAs) that recognize the target DNA can generate
double-strand breaks (DSBs) at specific DNA target
sites.20 Although the CRISPR/Cas9 system is effective,
off-target cleavage of Cas9 has been observed.21 This
problem of off-target cutting has been mitigated with
development of an engineered dual sgRNA system and
DNA ‘‘nickase’’ that was derived from Cas9 and creates
a single-stranded break (SSB).19 Thus, Cas9 nickases
(Cas9n) can be exploited for more specific CRISPR
editing,19 and this strategy could be applied to engineer
isogenic embryonic stem cell (ESC) and iPSC disease
models with specific mutations introduced or corrected,
respectively. Furthermore, this technology could be
applied in vivo as well as ex vivo.22
The purpose of the present study was to establish
GNASR201H-mutated (GNASR201H/+) iPSCs to obtain a
model for GNASR201H-related diseases. Toward this end,
we generated GNASR201H/+ iPSCs with Cas9n.
Materials and methods
Cell culture
The wild-type human iPSC line Nips-B2 (HPS0223)23
was purchased from Riken Bioresource Center
(Tsukuba, Japan). Before gene editing, iPSCs were
maintained with SNL76/7 feeder cells in human ESC
medium (Dulbecco’s modified Eagle medium/Ham’s F-
12 medium (DMEM/F12); Invitrogen, Carlsbad, CA,
USA) with 20% KnockOut Serum Replacement
(Thermo Fisher Scientific, Waltham, MA, USA) sup-
plemented with 13 non-essential amino acids (Merck,
Billerica, MA, USA), 2-mM l-glutamine (Thermo
Fisher Scientific), 0.11-mM 2-mercaptoethanol (Wako
Pure Chemical Industries, Ltd., Osaka, Japan), 1%
penicillin/streptomycin (Thermo Fisher Scientific), and
5-ng/mL human basic fibroblast growth factor (bFGF;
ReproCELL Inc., Yokohama, Japan). We cultured the
iPSCs without feeder cells. For feeder-free culture,
iPSCs were plated on an iMatrix-511 (Nippi Inc.,
Tokyo, Japan)-coated 60-mm dish and cultured in
StemFit AK02N medium (Ajinomoto Co., Inc.,
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Tokyo, Japan) supplemented with 1% penicillin/strep-
tomycin. The culture medium was replaced daily.
Targeting donor vector construction
The targeting donor vectors (pDONR-P3P1R, pDONR-
P2rP4, pENTR, and pDEST) were kindly provided by
Dr Takefumi Sone and Dr Hideyuki Okano. The left
arm of the target vector was designed to contain exon 7
and an intron between exons 6 and 7 of the GNAS gene
(NG_016194.1). The right arm was designed to contain
exons 8–10 with the R201H mutation. The right and left
DNA fragments were artificially synthesized (Genewiz,
Suzhou, China) and inserted into pDONR-P2rP4 (right
arm) and pDONR-P3P1R (left arm) using Gateway BP
clonase II enzyme mix (Thermo Fisher Scientific).
pDONR and pENTR vectors containing phosphoglyce-
rate kinase (PGK), the murine PGK promoter, a
puromycin-resistance gene (Puro), and an N-terminal
shortened version of herpes simplex virus type 1 thymi-
dine kinase (DTK) were cloned into pDEST using
Gateway LR clonase II enzyme mix.
SgRNA design and cloning
The sgRNAs were designed for the human GNAS locus
located on chromosome 20 with the CRISPR design
tool (http://crispr.mit.edu/). A pair of sgRNAs was
designed targeting the intron between exons 7 and 8, so
that they were sufficiently close (within 4-bp distance)
to generate a DSB. The complete sequences and loca-
tions of the sgRNA target sites are shown in Figure
1(a) and (b). Oligo pairs encoding the 20-nucleotide
guide sequence were annealed and ligated into the plas-
mid pSpCas9 (BB) (formerly pX460; Addgene plasmid
ID: 48873).
CRISPR/sgRNA transfection in iPSCs
We transfected the CRISPR/sgRNA plasmids and tar-
geting vectors into Nips-B2 by electroporation using
the Neon Transfection System (Thermo Fisher Scientific)
according to the manufacturer’s instructions. Briefly,
iPSCs (1 3 106) were suspended in 100-mL electropora-
tion buffer and electroporated at 950V for 20ms with 2
pulses. Seven days after electroporation, puromycin
selection (0.25 mg/mL, #A1113802, Thermo Fisher
Scientific) was started. Individual colonies were picked
and expanded after 14days (Figure 1(c)).
Sequencing
DNA extraction was performed with the DNeasy
Tissue Kit (Qiagen AG, Switzerland) according to the
manufacturer’s instructions. Primers used for the poly-
merase chain reaction (PCR) are listed Table 1.
Sequencing reactions were carried out using the BigDye
Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems, Rotkreuz, Switzerland) and analyzed with
the ABI Prism 3130 Genetic Analyzer (Applied
Biosystems, Rotkreuz, Switzerland).
Cell proliferation assay
We measured cell proliferation using WST-1 prolifera-
tion assay kit (MK 400: Roche Diagnostics GmbH,
Mannheim, Germany). We performed WST-1 prolif-
eration assay according to the manufacturer’s protocol.
Briefly, we cultured iPSCs at the density of 1 3 104 in
96-well plate and incubate for overnight. WST-1 solu-
tion was added to each well and incubated for another
30min at 37C. The absorbance at 450nm was mea-
sured and the reference wavelength was 650 nm.
Embryoid body formation
After the medium was removed, the cells were rinsed
twice with phosphate-buffered saline (PBS), and the
iPSCs were dissociated using a cell scraper and trans-
ferred to low-attachment Petri dishes to generate
embryoid bodies (EBs). EBs were maintained in human
ESC medium without bFGF for 21 days. The culture
medium was replaced every 3 days.
RNA isolation and reverse transcription
Total RNA was extracted using QIAzol reagent
(Qiagen Inc., Hilden, Germany) according to the manu-
facturer’s instructions. Complementary DNA (cDNA)
was synthesized using a high-capacity cDNA reverse
transcription kit (Applied Biosystems, #4368814). All
cDNA samples were stored at 220C. PCR was per-
formed with GoTaq (Takara, Japan). The KD human
lip fibroblasts (JCRB9103; JCRB Cell Bank, Osaka,
Japan) and distilled water (DW) were used as negative
control. Primer sequences used for the PCR are listed
in Table 2.
Alkaline phosphatase staining and
immunofluorescent microscopy
The iPSCs were washed twice with PBS, fixed in 4%
paraformaldehyde in PBS for 10min at room tempera-
ture, and washed twice with DW. The fixed cells were
stained with an alkaline phosphatase (ALP) substrate
solution (Roche Diagnostics, Basel, Switzerland) for
30min at room temperature.
For immunocytochemistry, after fixation and wash-
ing with PBS, the cells were incubated with the primary
antibodies against the following molecules: NANOG
(Wako, Japan; 1:200 dilution), SSEA-4 (R&D Systems;
1:100 dilution), and TRA1-60 (R&D Systems; 1:100
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Figure 1. Generation of GNASR201H iPSCs using the CRISPR/Cas9 system. (a) gRNA sequences (5#–3#). (b) CRISPR-mediated
genome editing and genotyping strategy for the GNAS gene. The targeting vector containing a puromycin-resistance gene flanked
with loxP. The left arm contains the exon 7 sequence, and the right arm contains the R201H mutation. The primers for target clone
selection are indicated with red and blue arrows. (c) Protocol for gene editing of GNAS+/+ iPSCs.
Table 1. Sequence primer.
Sequence primer
Primer name Forward primer sequence Revers primer sequence
Right side primer 1 ctatagatcctctagagtcgagggc tcaggagtagtgtagcgagcaaattc




pDEST primer ctatacaaagttgatagcttgatatcaat gggatatctgaattatcaactttgtata
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dilution) for 60min at room temperature. The second-
ary antibodies were fluorescein-conjugated anti-rabbit
IgG (H+L) (VECTOR; 1:200 dilution) and fluorescein-
conjugated anti-mouse IgG (CAPPEL; 1:1000 dilution).
Teratoma formation
The iPSCs cells (1 3 106 cells in 20-mL PBS) were
injected into the testis of 8- to 10-week-old male CB17
SCID mice (Charles River). Teratomas were resected 9–
12weeks after injection, fixed with 10% neutral-
buffered formalin for 24h, and paraffin-embedded sec-
tions (4 mm) were processed and stained with hematoxylin
and eosin. All mouse studies were carried out according to
protocols approved by the Animal Research Committee
of Tokyo Dental College (No. 270401).
cAMP assay
cAMP accumulation was measured using homogeneous
time-resolved fluorescence (HTRF) cAMP dynamic
kits (CisBio, Codolet, France) according to the manu-
facturer’s protocol. iPSCs were cultured in 96-well
plates (20,000 cells/well) and treated with parathyroid
hormone (PTH) (100 nM; Sigma-Aldrich, Buchs,
Switzerland)24 or adrenocorticotropic hormone
(ACTH) (10nM; Sigma-Aldrich, Buchs, Switzerland)25
along with 500-nM 3-isobutyl-1-methylxanthine
(IBMX; Cayman Chemical, Ann Arbor, MI, USA). At
each time point, the cells were lysed with 1% Triton X-
100. cAMP accumulation was detected by HTRF
(lex=330nm, lem=665 and 620nm) using a micro-
plate reader (Synergy, BioTek, Winooski, VT, USA).
Protein extraction and immunoblotting
The iPSCs were lysed in the RIPA Lysis Buffer with 2-
mM PMSF, 1-mM sodium orthovanadate and inhibitor
cocktail (Santa Cruz Biotechnology) and protein con-
centrations were measured by a Qubit Protein Assay
kit (Invitrogen). Equivalent protein concentrations were
resolved by electrophoresis on SuperSepAce 5%–
20% gels (Wako) and transferred to a PVDF mem-
brane. The membrane was probed with anti-GNAS and
Anti-beta Actin antibody (1:2000; Proteintech and
Abcam), followed by horseradish peroxidase-conjugated
goat anti-rabbit IgG and horseradish peroxidase-
conjugated anti-mouse IgG. Bound antibodies were
visualized using a chemiluminescent substrate (ECL
Primer Western Blotting Detection Reagent; GE
Healthcare Ltd., Buckinghamshire, United Kingdom)
and the ImageQuant LAS4000 mini instrument (GE
Healthcare).
Immunohistochemistry
Mouse monoclonal antibodies (anti-CK18: clone DC-
10, 1:500; anti-MUC1: clone Ma695, 1:500; anti-
MUC2: clone Ccp58, 1:500; anti-MUC5AC: clone
CLH2, 1:500; anti-MUC6: clone CLH5, 1:500; anti-
CEA: clone 12-140-10, 1:500; anti-CA19-9: clone
C241:5:1:4, 1:500, Novocastra, Leica Biosystems,
Newcastle, United Kingdom) and mouse and rabbit
monoclonal antibodies (anti-beta III tubulin: clone
2G10, 1:200; anti-NeuN: clone EPR12763, 1:200,
Abcam, Cambridge, Massachusetts, USA) as neural
tube labeling were used for immunohistochemistry.
Four-micrometer-thick sections were deparaffinized
Table 2. RT-PCR primer.
RT-PCR primer














PCR: polymerase chain reaction.
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and pre-treated with Epitope Retrieval Solution
(EDTA, pH: 8.8) at 98C for 20min. Peroxidase block-
ing was carried out for 10min using the Bond Polymer
Refine Detection Kit DC9800 (Leica Microsystems).
The tissues were incubated with the primary antibody
for 4C overnight, washed four times with Tris-buf-
fered saline, and incubated with peroxidase-labeled
anti-mouse antibody (Histofine SimpleStain MAX PO,
Nichirei, Tokyo, Japan) at 37C for 30min. Peroxidase
activity was detected with diaminobenzidine (DAB) for
10min. Qualitative and semi-quantitative analyses of
MUC1, MUC2, MUC5A, MUC6, CK18, CDX2,
CEA, and CA19-9 expression were performed for the
epithelia of ductal structures (ductal structures with a
single epithelial layer). Tissue sections were examined
under a light microscope using a 43 objective. The
pictures were edited with the AxioVision imaging pro-
gram (version 4.7.1). Thirty ductal structures in each
section from teratomas derived from control and
mutated GNAS iPSCs (four teratomas each) were
appraised using the following scoring system. Semi-
quantitative analysis was performed based on the per-
centage of positive ductal structures according to the
following criteria: 0, no detectable staining; 1+, \25%
positive ductal structure; 2+, 25%–49%; 3+, 50%–
74%; 4+, .75%. In addition, immunostaining inten-
sity was classified according to the following para-
meters: 1 (absent or weak expression) or 2 (strong
expression). The staining score was then obtained by
multiplying the percentage and intensity scores as the
final immunoreactive score (IRS), which was subjected
to statistical analysis.
Statistical analysis
Means of semi-quantitative scoring were analyzed using
the Student t-test or the Mann–Whitney U test (SPSS
for Windows, version 17). All data are expressed as the
mean 6 standard deviation (SD, p \ 0.05).
Results
Establishment of GNASR201H iPSCs using CRISPR/
Cas9
We performed iPSC gene editing and puromycin selec-
tion of edited clones and confirmed that the shape of
the edited iPSC colonies was similar to that of the
GNAS+/+ iPSCs (Figure 2(a)). The single base substitu-
tion that introduced the R201H mutation in the GNAS
gene was confirmed in 2 out of 24 clones that survived
after puromycin selection (Figure 2(b) and (c)). There
were no significant differences in cell proliferation rates
among these clones (Supplemental Figure 1).
Characterization of GNAS-mutated iPSCs
Expression of ESC marker genes (NANOG, OCT3/4,
SOX2, REX1, KLF4, and c-MYC) and ALP positivity
were confirmed in GNASR201H/+ iPSCs (Figure 3(A)
and (B)). Immunofluorescence staining demonstrated
that all cells were positive for SSEA4, NANOG, and
TRA1-60 (Figure 3(C)). We grew GNASR201H/+ iPSCs
as free-floating cultures to form EBs (Figure 3(D)). The
EBs maintained in free-floating culture conditions
expressed markers of all three germ layers: MAP2 and
PAX6 as ectodermal markers, MSX1 and
BRACHYURY as mesodermal markers, and AFP and
SOX17 as endodermal markers (Figure 3(E)).
Teratomas were removed, fixed, paraffin-embedded,
and sectioned (4 mm) for hematoxylin and eosin stain-
ing, which also identified tissues representing all three
germ layers, including neural tube-like structures and
melanocytes as in the ectoderm (Figure 3(F)(a) and
(b)), cartilage as in the mesoderm (Figure 3(F)(c)), and
a gut-like epithelium as in the endoderm (Figure
3(F)(d)). Neural tube-like structures revealed positive
staining for both beta-tubulin and NeuN, confirming
that these structures were indeed neural tubes
(Supplemental Figure 2).
Measurement of intracellular cAMP accumulation
Gsa is expressed ubiquitously and there appears to be
no parental allele bias in patients with MAS or other
GNASR201H-related diseases. Thus, it is assumed that
the GNAS activating mutation GNASR201H must cause
a dominant effect in generating cAMP due to the con-
stitutive activation of Gsa. Accordingly, we examined
the changes in cAMP levels upon PTH and ACTH sti-
mulation. We measured the expression of intracellular
cAMP levels at the steady state by HTRF. Compared
with that of GNAS+/+ iPSCs (Nips), the intracellular
cAMP levels of GNASR201H/+1 and GNASR201H/+2
were significantly increased (Figure 4(a)). In addition,
the cAMP levels of GNASR201H/+1 iPS and
GNASR201H/+2 were elevated upon ACTH and PTH
treatment (Figure 4(b)). No significant difference in
Gsa protein level was observed between all iPS clones
(Figure 4(c)).
Ductal structures in MAS iPSC-derived teratomas
have less mucin but more CEA and CA19-9
Despite the fact that GNAS mutations are frequently
observed in many gastrointestinal benign tumors,
including IPMN, the lack of adequate cell models has
restricted the knowledge and studies on its pathological
roles in tumor development. Therefore, to investigate
whether GNAS mutations cause any changes in
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functional or differentiation phenotypes, we investi-
gated the protein levels of MUCINs (MUC1, 2, 5AC,
and 6), CK18, CDX2, CEA, and CA19-9. We used
MUCIN expression as a functional marker of gastroin-
testinal or pancreatic epithelial cells. Mucins are
secreted from ductal epithelial cells to cover its mucosa
surface, and play an important role in protecting the
mucosa surface, and are also used as lubricants and
surfactants. There are several subclasses of mucins
whose localizations are mostly tissue-specific. Thus,
they are recognized as tissue-specific markers. Indeed,
mucins are used as a differentiation marker as well as a
functional marker in immunohistochemical examina-
tions for the diagnosis of several tumors. CDX2 is
another marker of intestinal and colon epithelium,
CK18 is a differentiated epithelial cell marker, and
CEA and CA19-9 are standard tumor markers.
We observed many MUC1-, MUC2-, and MUC5A-
positive ducts in control iPSC-derived teratomas
(Figure 5(a)). Every subclass of mucins was detected at
much lower levels in GNAS-mutated iPSC-derived
teratomas. However, there was no difference in the
level of CDX2 positivity in ductal structures between
the control and GNAS-mutated iPSC-derived terato-
mas. We observed weak CEA and CA19-9 positivity in
control iPSC-derived teratomas and strong CEA and
CA19-9 positivity in ductal structures from GNAS-
mutated iPSC-derived teratomas (Figure 5(a)–(c)).
Most of the ductal structures in the control teratomas
were CK18-positive, whereas the structures from
GNAS-mutated iPSC-derived teratomas were not
(Figure 5(c)).
Discussion
In this study, we generated disease-specific iPSCs with
the GNASR201H mutation using the CRISPR nickase
system. Pathological mechanisms regarding
GNASR201H mutations are yet to be clarified due to the
lack of human cell model systems.26 However, the
GNASR201H/+mutation is a rare somatic mutation, and
it is often not feasible to establish cultured cells from
Figure 2. Confirmation of genome editing using RT-PCR and Sanger sequencing. (a) Morphology of GNASR201H iPSCs. Parental
iPSCs (Nips iPSCs) used in the experiment and gene-edited GNASR201H/+ iPSCs. Scale bars: 200 mm. (b) We selected two clones
with targeting vector sequences in the designated positions. The PCR product of the left arm was 950 bp, and the PCR product of
the right arm was 900 bp. (c) We confirmed the designed mutations by Sanger sequencing. The R201H (cgt ! cat) mutation in exon
8 was confirmed in both colonies.
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patients. Although the establishment of iPSCs derived
from FD patients was recently reported, they did not
generate the ‘‘revertant’’ iPSCs, in which the mutation
is corrected to the wild type with the same genetic
background.27 To overcome this obstacle, we generated
artificially mutated GNASR201H/+ iPSCs. We used a
double nicking strategy with Cas9n instead of
CRISPR/Cas9 to avoid off-target effects.28 This strat-
egy uses paired Cas9ns that introduce nicks in each
DNA strand, causing site-specific DSBs. This technique
is highly specific because DSBs occur only when two
nickases work simultaneously (Figure 1(b)). To identify
pluripotent cells, we measured the expression of stem
cell markers and teratoma formation after transplant-
ing iPSCs into immunocompromised mice, and con-
firmed that the GNASR201H/+-mutated iPSCs exhibit
pluripotency.
As GNAS is an imprinted gene,29 it is possible that
introduced mutations may not be transcribed and
translated. Therefore, we confirmed the presence of the
Figure 3. Confirmation of GNASR201H iPSC pluripotency. (A) RT-PCR for the expression of embryonic stem cell markers in
GNASR201H iPSCs. ACTB was used as an internal control. KD fibroblasts and distilled water DW were used as negative controls. (B)
Alkaline phosphatase (ALP) activity of GNASR201H. (C) Immunofluorescence analysis of pluripotency markers (NANOG, SSEA4, and
TRA1-60) for GNASR201H iPSCs. Nuclei were stained with DAPI. Scale bars: 200 mm. (D) Embryonic bodies were generated from
GNASR201H/+ iPSC cells expressing the marker genes of the three germ layers. Scale bars: 100 mm. (E) MAP2 and PAX6 were used as
ectodermal markers, MSX1 and BRACHURY were used as mesodermal markers, and AFP and SOX17 were used as endodermal
markers. ACTB was used as an internal control. KD fibroblasts and DW were used as negative controls. (F) Representative tissues of
the three embryonic germ layers in teratomas, including neural tube-like structures (a) and melanocyte-like cells (b) (ectoderm),
cartilage (c) (mesoderm), and gut-like epithelium tissues (d) (endoderm).
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GNAS mutation with sequencing and functional GNAS
activation by examining the effects of hormones that
bind to GPCRs. We focused on two hormones as
GPCR ligands, PTH and ACTH. PTH is often a target
of diseases caused by inactivating mutations within
Gsa-coding GNAS exons. ACTH is an ACTH, and its
overactivation causes Cushing disease, one of the phe-
notypes in MAS.30 As expected, we observed a rapid
production of cAMP after ACTH or PTH stimulation
and a higher level of sustained cAMP production in
mutated iPSCs compared to parental iPSCs.
GNAS encodes a G protein a subunit that is associ-
ated with GPCRs. Over 800 different GPCRs are
encoded in the human genome, and nearly a third of all
drugs target this type of receptor.31,32 Their ligands
include hormones, neurotransmitters, and odor mole-
cules or proteins identified by sequence homology, but
there are also so-called orphan receptors without
known ligands.31 Many diseases associated with GNAS
hyperactivation have been reported due to its involve-
ment in a wide spectrum of biological activities.33
GNASR201H/+ mutations are associated with
gastrointestinal neoplasms, including pancreatic
IPMNs and invasive adenocarcinomas arising from
IPMNs, colonic adenocarcinomas, and mucinous
appendiceal tumors.34–36 GNASR201H+ mutations are
reported in up to two-thirds of pancreatic IPMNs.37 In
addition, approximately 2% of colonic adenocarcino-
mas harbor GNAS mutations, and are associated with
a villous morphology. Therefore, GNASR201H muta-
tions seem to play an important role in tumorigenesis.
Both villous adenoma and IPMN, which are benign
tumors prone to malignant transformation, frequently
harbor GNAS mutations. However, progress in eluci-
dating the pathological conditions and developing ther-
apeutic methods has been very slow. iPS cells can be
induced into the digestive tract and pancreas; thus, our
iPS cells can be used as a tool for examining the tumor-
igenesis mechanism and discovering effective treatment
strategies. A recent study demonstrated that medullo-
blastoma was frequently detected in teratomas pro-
duced by transplanting iPSCs derived from patients
with Gorlin syndrome, where medulloblastoma fre-
quently occurs.38 Thus, even though a teratoma is
Figure 4. cAMP production in GNASR201H/+1 and GNASR201H/+2 iPSCs treated with G- protein coupled receptor (GPCR) ligands.
(a) cAMP production was examined in GNASR201H/+1 and GNASR201H/+2, and in GNAS+/+Nips iPSCs. The iPSCs were cultured in
conventional ESC medium. Even without GPCR ligand stimulation, the basal level of cAMP in GNASR201H iPSCs was higher than that
of parental iPSCs (Nips). Six independent experiments were performed. Data are shown as the means 6 standard deviation.
Student’s t-test was performed to validate the differences between two groups. *p \0.05. (b) cAMP production upon GPCR
treatment. We examined the effects of stimulation with two hormones: parathyroid hormone (PTH) and adrenocorticotropic
hormone (ACTH). cAMP generation increased upon hormone stimulation in GNASR201H iPSCs. Data are the means 6 standard
deviation from two independent experiments, each measuring six samples. *p \0.05 GNASR201H iPSCs vs GNAS+/+ iPSCs at the
same time point. (c) Gsa protein levels were examined by immunoblotting.
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Figure 5. Immunohistochemical analysis of teratomas generated by transplantation of iPSCs into immunocompromised mice. (a)
Fifty luminal structures surrounded with simple epithelial cells were selected. Immunohistochemical staining of mucins, CK18,
CDX2, CEA, and CA19-9 was performed. Luminal structures in control iPSC-derived teratomas were positive for MUC1, MUC2,
and MUC5AC. Almost half of the luminal structures in control iPSC-derived teratomas were CDX2-positive. Most of the epithelial
cells were CEA-positive and faintly CA19-9 positive. Scale bars: 500 mm. (b) Fifty luminal structures surrounded with simple
epithelial cells were selected and immunohistochemical staining was performed. We found less MUC1-, MUC2-, and MUC5AC-
positive cells in GNASR201H iPSC-derived teratomas. CK18-positive cells were seldom observed. Almost half of the luminal
structures of simple epithelial cells were CDX2-positive. There was strong positivity for CA19-9 and CEA in luminal structures.
Scale bars: 500 mm. (c) Immunoreactivity scores (IRS). Data are the means 6 standard deviation from GNASR201H iPSCs-derived
teratoma and control GNAS+/+ iPSC-derived teratomas, with 30 luminal structures measured per group.
*p \0.01, GNASR201H iPSCs vs GNAS+/+ iPSCs.
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overall benign, it is possible that some parts of the tera-
toma will harbor a trait that makes them prone to
cancer.
To evaluate the epithelial structures often affected in
GNAS-mutated tumors, we examined differentiation
markers such as mucins (MUC1, 2, 5A, and 6), CK18,
and CDX2. We also investigated the distribution of
CEA and CA19-9 as markers of malignant tissues,
which offered insight into the differential state that
could contribute to malignant potential.
Mucin is a functional protein secreted by many duc-
tal epithelial cells and has many tissue-specific subtypes.
The distribution of different mucin subclasses varies
depending on the pancreatic or colon tumor pathologi-
cal phenotype; thus, it is useful for pathological and
prognostic diagnosis39–41 Owing to its specificity, mucin
has been widely applied for pathological diagnosis
using immunohistochemical staining. The distribution
of mucin subclasses in lesions differs from that in nor-
mal tissues. For example, in Barrett’s esophagus, the
pattern of mucin expression differs from that of the eso-
phagus. Moreover, the distribution of mucin expression
reflects the origin of the adenocarcinoma (esophageal
type, gastric type, and intestinal type). Gastric goblet
cells are MUC2-positive, and in gastric cancer tissues,
MUC5AC is positive on the apical side, whereas
MUC6 is positive on the basement membrane side.
GNASH201C mutation is common in villous adenoma,
which is considered to be a low-grade malignancy, and
is also characterized by MUC5AC and MUC2 expres-
sion. The most typical IPMN is characterized by both
MUC5AC and MUC2 expression. However, no com-
prehensive study has been conducted to evaluate the
difference in staining properties of mucin from those of
normal tissues. Therefore, we examined the immunohis-
tochemical staining of mucin between normal and
GNAS-mutated teratoma tissues. Based on the fact that
the GNAS mutation was frequently observed in gastric
villous adenoma and pancreatic IPMN, immunohisto-
chemical staining patterns of mucin were compared
between tissues with wild-type and mutated GNAS.
The results showed decreased staining for every subtype
of mucin in the samples with mutated GNAS, suggest-
ing that the production of mucin, which is a functional
protein, might be decreased in tumors caused by GNAS
mutations. Therefore, we examined mucin expression in
luminal structures from iPSC-derived teratoma tissues.
The same number of luminal structures was examined
in control and GNAS-mutated iPSC-derived teratomas;
luminal epithelial cells of control teratomas were posi-
tive for MUC1, MUC2, and MUC5A as well as for
CK18. GNAS-mutated luminal structures had much
less mucins and CK18 positivity; almost no CK18-posi-
tive epithelial cells were found in GNAS-mutated iPSC-
derived teratomas. In contrast to the negative staining
observed for mucins and CK18, CEA and CA19-9
frequently show strong positive staining in GNAS-
mutated teratomas.42,43
Taken together, these findings indicate that most of
the mucins investigated and CK18 are epithelial cell
markers, and are expressed on most of the luminal
epithelial cells of the normal iPS-derived teratoma but
are weakly expressed in GNASR201H+ iPS-derived tera-
tomas. It is speculated that the extreme decrease in the
expression levels of all types of mucins as well as CK18,
and the more intense positivity of CEA and CA19-9
may indicate that these luminal structures have distinct
differentiation patterns from normal structures. This
may be caused by undifferentiated or dysplastic proper-
ties, developmental abnormalities, or low epithelial
functional properties.
To date, only postzygotic mutations (R201C and
R201H) have been reported in humans, such as in
MAS; in contrast, germline mutations (R201C and
R201H) have seldom been reported.44 Lack of inheri-
tance of the disease in humans is considered to reflect
the embryonic lethality of germline-transmitted activat-
ing Gsa mutations, which would only survive through
somatic mosaicism. Thus, properly controlled GNAS
function is likely critical for a proper epithelial pheno-
type, further supporting that GNAS dysfunction leads
to dysplastic or malignant tumor development.
Inducing gastrointestinal or pancreatic organoids may
provide a clue to reveal the pathogenesis of GANS
R201H mutation-related tumors.
Conclusion
GNASR201H mutations are rare but play a crucial role
in tumorigenesis. Unfortunately, it has not been feasi-
ble to establish primary cell cultures from patients with
these mutations. We succeeded in generating artificially
mutated GNASR201H iPSCs. The model developed
herein holds promise for determining the detailed
pathological mechanisms of diseases with mutated
GNAS. Although further studies, such as the genera-
tion of gastrointestinal or pancreatic organoids, are
warranted, we believe that the new cell line generated in
our study has potential for use as a model in the identi-
fication of novel therapies to combat these diseases.
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